The stock of Pacira BioSciences Inc. (NASDAQ:PCRX) decreased by -$0.25 on Friday to finish at $37.57, down -0.66 percent. The last five days have seen an average of 461,700 shares of common stock traded. 11 times new highs were reached in the current year, with a fall of -$1.04. The average number of shares traded over the last 20 days was 678,150, while the average volume over the last 50 days totaled 636,046.
PCRX stock appreciated 0.83% since last month. On 08/02/23, the company’s shares reached a one-month low of $34.08. The stock touched a high of $58.74 on 05/01/23, after rallying from a low of $34.08 in 52 weeks. The price of PCRX stock has declined by -2.69% or -$1.04 this year, reaching a new high 11 times. Still, the stock price is down -36.04% from the 52-week high.
Insider Transactions
PCRX stock investors should be aware that Pacira BioSciences Inc. (PCRX) stock had its last reported insider trading activity 12 days ago on Aug 02. On Aug 02, Chief Medical Officer WINSTON ROY sold 509 shares at $34.88 each. This transaction resulted in the insider making $17,751. On Jul 05, Riker Lauren Bullaro sold 643 shares at a price of US$38.91. After the transaction, the insider now owns 22,687 shares. Senior Vice President, Finance Riker Lauren Bullaro had earlier sold 6,366 shares on Jun 14 for $38.42 a share. The transaction was completed for $244,606.
Valuation Metrics
Beta for the stock is 0.68. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.62, the price-to-book (PB) ratio of 2.14, and the price-to-cash flow ratio of 13.86.
Financial Health
For the three months ended June 29, Pacira BioSciences Inc.’s quick ratio was 3.10, while its current ratio was 3.90, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.66, and the total debt to equity ratio is 0.68. As far as profitability goes, gross margin for the trailing twelve months is 68.60% percent. Pacira BioSciences Inc.’s EBITDA margin for the year ended June 29 was 24.36%, whereas its operating margin stood at 4.70% for the same period. Based on annual data, it had gross profit of $467.53 million and revenue of $666.82 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PCRX’s return on assets (ROA) during the last 12 months has been -0.30%. There was a 4.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -0.60%.
Earnings Surprise
According to Pacira BioSciences Inc.’s quarterly financial report for the quarter that ended June 29, it had $134.82 million in total debt versus $133.96 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $169.47 million, while revenues rose by 0.04% to $160.34 million. It was predicted that Pacira BioSciences Inc.’s quarterly earnings would be $0.78, but it ended up being $0.76, beating the consensus by 2.60%. EBITDA was $59.65 million for the quarter. At the end of Pacira BioSciences Inc.’s most recent quarter ended June 29, its liabilities totaled 734.41 million, while its total debt was $620.71 million. Equity owned by shareholders amounts to $46.42 million.
Technical Picture
Here’s a quick look at Pacira BioSciences Inc.’s (PCRX) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 49.28%, suggesting the stock is Neutral, with a 36.97% historical volatility rate.
The stochastic %K and %D were 61.46% and 64.27% respectively, while the average true range (ATR) was 1.53. Based on the 14-day stochastic reading of 57.40%, the RSI (14) reading is 48.80%. On the 9-day MACD Oscillator, the stock is at -0.04, and the 14-day reading is at 0.50.
Analyst Ratings
In its most recent analyst report, TD Cowen raised its rating on Pacira BioSciences Inc. (NASDAQ: PCRX) to an Outperform. Prior to this, analysts firm rated the stock as a Market perform. Analysts have assigned Pacira BioSciences Inc. (PCRX) an Buy rating. PCRX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 8 others recommend it as a buy.
What is PCRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $46.00 and $70.00, with a median target price of $55.00. In analyzing these forecasts, the average price target given by analysts for Pacira BioSciences Inc. (PCRX) is $55.89.
